Your AI-Trained Oncology Knowledge Connection!
Overall, the findings highlight the potential of bispecific antibodies as salvage therapy post anti-CD19 CAR T cell treatment and challenges associated with allogeneic hematopoietic cell transplantation consolidation after bispecific antibodies therapy in patients with relapsed/refractory B-cell lymphomas .
During a Morning Rounds discussion, experts in the field of renal cell carcinoma reviewed treatment updates and the effective use of immunotherapy plus TKIs.
Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Neil M. Iyengar, MD, gives new directions and ideas as he begins his new position as co–editor-in-chief of ONCOLOGY.
Kristen K. Ciombor, MD, MSCI, gives an overview of the current treatment landscape for patients with metastatic colorectal cancer.
Misako Nagasaka, MD, PhD, sheds light on neoadjuvant and adjuvant treatment options for patients with lung cancer.
During the European Society for Medical Oncology 2023, experts discussed updated results in key trials across the lung cancer space.
Patients with chronic lymphocytic leukemia in the ALPINE study previously treated with BTK inhibitors are likely to remain sensitive to other BTK-targeting agents, says Jennifer Brown, MD, PhD.
During a continuing medical education activity hosted by PER, Paolo Tarantino, MD, discussed HER2-low breast cancer and emerging treatment options to fight the disease.
Pirtobrutinib produces a high rate of responses in patients with relapsed chronic lymphocytic leukemia harboring baseline BTK mutations, according to findings from the phase 1/2 BRUIN trial.
The application for amivantamab and lazertinib for locally advanced or metastatic non–small cell lung cancer is supported by data from the phase 3 MARIPOSA trial.
DZD8586 results in favorable safety with limited grade 3 or greater treatment-emergent adverse effects in those with B-cell non-Hodgkin lymphoma, according to data from 2 ongoing phase 1 trials.
“KRAS is probably the most exciting area in clinical trials right now, not only in thoracic oncology but also pancreatic and colorectal cancer, where we’ve seen a lot of combination therapies. My view is the small molecule inhibitors are the base, not the ceiling.”
Investigators indicate that, although treatment with adjuvant/neoadjuvant pembrolizumab results in an absolute decrease in risk of an event, the benefit was not statistically significant in those with untreated, locally advanced gastric/GEJ cancer.
The on-body injector, pegfilgrastim-cbqv, has been approved by the FDA for patients who experience febrile neutropenia after chemotherapy.
Data from the phase 3 SEQUIOA trial may support zanubrutinib as a best-in-class Bruton tyrosine kinase inhibitor in the frontline management of chronic lymphocytic leukemia.
A panel of experts spoke about the armamentarium of bispecific antibody therapies for patients with relapsed/refractory multiple myeloma and discussed step-up dosing considerations for these approved agents.
It may be possible to use anastrozole plus palbociclib, trastuzumab, and pertuzumab in place of chemotherapy in the frontline setting for hormone receptor–positive, HER2-positive metastatic breast cancer, says Amy Tiersten, MD.
A future phase 2 trial may compare anastrozole plus a CDK4/6 inhibitor and trastuzumab or pertuzumab with chemotherapy plus trastuzumab and pertuzumab in hormone receptor–positive, HER2-positive metastatic breast cancer.
Oncoplastic surgery requires collaboration between different surgical teams, pathologists, and radiologists to ensure optimal cosmetic and survival outcomes for patients with breast cancer, says Roshani Patel, MD, FACS.
Belumosudil is the first therapy within England and Wales available for the treatment of patients 12 years and older who have previously undergone a minimum of 2 lines of systemic treatment.
During or after cancer treatment, patients may experience sexual dysfunction leading to a decrease in their quality of life.
After originally releasing the Medicare Prescription Drug Inflation Rebate Program in February 2023, CMS has issued changes which address ongoing drug shortages.
Lower risk of disease progression following treatment with atezolizumab and carboplatin for metastatic triple-negative breast cancer appears to be associated with increases in tumor infiltrating lymphocytes and tumor mutational burden.
